Willow Bioscience CEO Dr Chris Savile joined Steve Darling from Proactive to share news the company has agreed to a Master Services Agreement with an innovative biotech company with the focus on age-related diseases. This partnership will see the company develop precision fermentation processes for a class of molecules to develop novel solutions for age-related diseases.
Savile also told Proactive about another key partnership with Kalsec Inc to develop an enzyme used in production of a new, advanced ingredient used in natural beverage applications. This is now the second collaborative development program the two parties will be working on. The goal is to commercialize these products quickly and effectively, leveraging partnerships for market access while retaining the option to bring proprietary ingredients to market independently.